Stoke Therapeutics, Biogen report 4-year open-label data for Dravet drug zorevunersen showing durable seizure reduction
STOK•Four-year open-label data show durable seizure reduction
Stoke Therapeutics and Biogen flagged long-term zorevunersen data for Dravet syndrome, scheduled for presentation at the European Epilepsy Congress.
Long-running extension studies showed sustained seizure control, with continued gains in cognition, behavior and quality of life over multiple years.
An exploratory analysis indicated fewer severe seizure types linked to SUDEP risk, supporting a potential disease-modifying profile.
The pivotal Phase 3 EMPEROR trial finished enrollment for its primary analysis population, with results expected in Q3 2027.
Stoke plans a rolling FDA NDA in H2 2027 if Phase 3 data support filing, and long-term dosing remained generally well tolerated.
